Pricing Log in Create free account
Friday 6 November 2026 Export AGL’s income statement to Excel — free account

Agilon Health, Inc.

AGL Healthcare Medical Care Facilities

Agilon Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.9 billion, down 2.11% from fiscal 2024.

Revenue
+5.86%
EPS
+130.8%
Free cash flow
+234.4%
Total debt
−12.7%

Quarter to September 2026, against a year earlier

110.84 14.61 +15.18%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−47.6×
Dividend yield
—
F-score
3/9
Altman Z
1.45
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.30
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — 4 — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 30.21%

Capital & Financial Ratios $m

Size
Market Cap 1,910.00
Revenue ttm 6,004.18
Net income ttm (87.10)
Free cash flow ttm (17.01)
Net debt Q (281.21)
Valuation
P/E 0.00
Forward P/E (47.60) (negative: loss-making)
Price / sales 0.31
Forward P/S Powerpack
Price / FCF 0.00
Price / book 6.63 (above 6: high)
Financial health
Current ratio Q 1.14
Debt / equity Q 0.11 (at or below 0.5: strong)
Interest coverage Q 13.82
Growth
Revenue growth Q +5.86% (above 0%: growing)
Operating income growth Q +118.37% (above 0%: growing)
EPS, this year +95.66% (at or above 15%: strong)
EPS, next year A +335.18% (at or above 15%: strong)
Revenue, next year A +9.13%
EPS, past 5 yrs —
EPS, next 5 yrs A +79.96% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.3×, against a ten-year median of 0.5×; over the ten years it ranged from 0.0× in 2026 to 9.2× in 2021.
P/S against its own 10 years 36.77%
10-year low 10-year high
P/B against its own 10 years 55.17%
10-year low 10-year high
EV/Sales against its own 10 years 35.29%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 495 406 285 312
Receivables 942 1,017 674 1,017
Inventory — — — —
Other — — — —
1,480 1,458 1,097 1,400
2023 2024 2025 Q'26
Payables 239 220 127 326
ST’ Debt 6 — 19 15
Other — — — —
977 1,152 1,076 1,233

Compound Annual Growth %

10y 5y 3y
Sales 22.28% 37.24% 35.43%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% (50.43%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −2.01 Actual 1.97

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −6.75 −11.50 Miss by 4.75
Q1 FY26 1.13 1.80 Beat by 0.67
Q2 FY26 0.06 1.04 Beat by 0.98
Q3 FY26 −2.01 1.97 Beat by 3.98
Q4 FY26 −3.65 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 2.94 1.04 1.97 — —
’25 0.75 (6.25) (6.75) (11.50) (23.75)
’24 (0.37) (1.75) (7.25) (6.50) (15.75)
’23 1.00 (1.00) (2.00) (14.25) (16.00)
’22 0.00 (1.25) (1.75) (3.50) (6.50)
’21 (1.25) (19.75) (2.25) (3.50) (27.25)
’20 (1.25) (0.61) (0.91) (1.87) (4.64)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1,420 1,495 1,519 — —
’25 1,533 1,395 1,435 1,569 5,933
’24 1,604 1,483 1,451 1,522 6,061
’23 1,054 1,069 1,137 1,056 4,316
’22 653 670 695 370 2,388
’21 413 499 459 151 1,521
’20 291 294 313 321 1,218
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 24 (57) 50 — —
’25 (32) (35) (18) (21) (106)
’24 (48) (19) (8) 16 (58)
’23 (61) (21) (13) (61) (156)
’22 (23) (60) 3 (50) (131)
’21 (41) (39) (19) (49) (148)
’20 (26) (9) (4) (13) (53)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 21 (62) 47 — —
’25 (43) (41) (35) (30) (149)
’24 (62) (28) (12) 4 (99)
’23 (65) (27) (19) (77) (187)
’22 (28) (76) (1) (58) (163)
’22 — — — — (131)
’21 (45) (40) (24) (52) (162)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 794 1,218 1,521 2,388 4,316 6,061 5,933 6,004 +39.8% 6,474 6,931 7,726 +9.2%
Gross margin, % — — — 3.59 7.73 4.32 4.66 1.61 0.08 (2.70) 0.00 (6.3) pt
EBT — — — (115) (62) (383) (91) (194) (249) (404) (101) +23.4%
EBT margin, % — — — (14.44) (5.12) (25.17) (3.80) (4.51) (4.11) (6.81) (1.68) +7.6 pt
Net income — 0 — (283) (60) (407) (107) (263) (260) (391) (87) n/m
Per share, $
Per share, $ Revenue — — — 67.38 94.16 102.00 146.28 263.89 368.68 358.27 357.54 +32.1%
Earnings — — — (23.98) (4.64) (27.25) (6.50) (16.00) (15.75) (23.75) (5.40) (0.2%)
Cash flow — — — (8.81) (4.11) (9.93) (8.01) (9.55) (3.51) (6.39) (0.25) (5.2%)
Capex — — — (0.33) (0.18) (0.90) (2.00) (1.88) (2.51) (2.60) (0.76) +41.0%
Free cash flow — — — (9.14) (4.29) (10.83) (10.01) (11.43) (6.03) (8.99) (1.01) (0.3%)
Book value — — — (19.68) (22.01) 73.18 63.74 40.41 28.65 7.65 16.73 n/m
Shares, m — — — 12 13 15 16 16 16 17 17 +5.8%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 7.53 7.53 6.62 2.74 1.22 0.13 0.05 0.31 3.7
P/B — — — 0.00 0.00 9.22 6.29 8.00 1.66 2.25 6.63 3.9
EV/Sales — — — 7.52 7.52 5.96 2.39 1.12 0.07 0.01 0.26 3.5
EV/FCF — — — (136.12) (136.12) (56.09) (34.88) (25.18) (4.23) (0.23) (41.54) (56.1)
Cash, $m
Cash, $m Operating cash flow — — — (104) (53) (148) (131) (156) (58) (106) (4) +0.3%
Capex — — — (4) (2) (13) (33) (31) (41) (43) (13) +49.2%
Free cash flow — — — (108) (56) (162) (163) (187) (99) (149) (17) +5.5%
Balance, $m
Balance, $m Working capital — — — 46 27 1,010 916 503 306 20 166 (12.8%)
Net debt — — — (69) (67) (1,006) (844) (457) (371) (250) (281) +24.0%
Shareholders’ equity — — — (232) (285) 1,092 1,041 661 471 127 281 n/m
Returns, %
Returns, % ROA — — — (70.14) (14.14) (40.00) (6.49) (15.27) (14.97) (26.04) (5.51) +44.1 pt
ROIC — — — 0.00 0.00 (273.14) (33.56) (70.95) (182.11) 0.00 0.00 0.0 pt
ROE — — — 121.80 23.24 (100.76) (9.99) (30.86) (45.96) (130.95) (29.68) (252.7) pt
People
People Employees — — — — 552 648 747 1,117 1,076 856 — +9.2%
Revenue/emp, $m — — — 0.00 2.21 2.35 3.20 3.86 5.63 6.93 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Agilon Health, Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ARDT Ardent Health, Inc. $2.2B 15.2× 12.8× +3.05% (above 0%: growing) n/m −23.49% (below 0%: shrinking) 100.00% 0.00% Compare
ASTH Astrana Health, Inc. $1.9B 46.8× 25.9× +48.52% (above 0%: growing) +110.53% (above 0%: growing) −67.74% (below 0%: shrinking) 10.70% 3.53% Compare
AGL Agilon Health, Inc. $1.9B — (loss-making) — (loss-making) +5.86% (above 0%: growing) n/m +234.38% (above 0%: growing) 0.00% 1.59%
AMN AMN Healthcare Services Inc $1.8B 17.4× 25.4× +2.29% (above 0%: growing) n/m −389.43% (below 0%: shrinking) 30.58% 4.00% Compare
HCSG Healthcare Services Group, Inc. $1.7B 16.6× 18.6× +3.29% (above 0%: growing) −37.29% (below 0%: shrinking) −59.81% (below 0%: shrinking) 16.76% 6.66% Compare
SNDA Sonida Senior Living, Inc. $1.6B — (loss-making) — (loss-making) +114.40% (above 0%: growing) n/m +360.11% (above 0%: growing) 35.68% (9.27%) Compare
PNTG The Pennant Group, Inc. $1.4B 37.3× 36.7× +31.96% (above 0%: growing) +55.56% (above 0%: growing) −3.19% (below 0%: shrinking) 13.34% 5.46% Compare
NUTX Nutex Health Inc. $1.3B 7.4× 7.3× −13.62% (below 0%: shrinking) n/m +19.44% (above 0%: growing) 67.04% 57.75% Compare
INNV InnovAge Holding Corp. $1.2B 124× 20.9× +12.14% (above 0%: growing) +155.00% (above 0%: growing) +622.82% (above 0%: growing) 24.02% 7.61% Compare
Median of peers $1.7B 17.4× 20.9× +7.72% +83.04% −13.34% 27.30% 4.73%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Directors and executive officers, together 2.50%
CD&R Vector Holdings, L.P. 24.10%
Morgan Stanley 12.10%
North Peak Capital Management, LLC 9.50%
BlackRock, Inc. 5.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Agilon Health, Inc. (AGL) Latest News

5 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat transcript

4 Nov

Impact 4 · · Business Wire
Impact 3 · · Associated Press
Impact 3 · · StockStory

23 Oct

Impact 3 · · Zacks

21 Oct

Impact 3 · · StockStory

8 Oct

Impact 4 · · Simply Wall St.

7 Oct

Impact 3 · · Zacks

30 Sep

Impact 4 · · Business Wire

23 Sep

Impact 4 ·

17 Sep

Impact 3 ·

10 Sep

Impact 3 ·

19 Aug

Impact 3 ·

13 Aug

Impact 3 ·

12 Aug

Impact 4 · · The Motley Fool transcript

7 Aug

Impact 3 ·

6 Aug

Impact 3 · · MarketBeat transcript

5 Aug

Impact 3 ·
Impact 3 ·
Impact 3 ·
Impact 3 ·

10 Jul

Impact 3 ·

6 Jul

Impact 3 ·

22 Jun

Impact 3 · · Insider Monkey

5 Jun

Impact 3 · · StockStory

20 May

Impact 4 · · Insider Monkey

16 May

Impact 3 · · StockStory

13 May

Impact 4 · · Simply Wall St.
stockrow.com/AGL · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com